SMARCC2 and central nervous system cancer: Next, data from 401 patients with gene mutation information were analyzed, and the mutation rate of SMARCC2 was found to be as high as 20% in gliomas, with loss of heterozygosity (HETLOSS) as a major component (Fig. 1D).